Josep Tabernero logo Vall d’Hebron Institute of Oncology (VHIO) logo

Josep Tabernero

Head, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH); Director, Vall d'Hebron Institute of Oncology, VHIO (Spain)


Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and he is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO) and Professor of Medicine at UVic. He is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with tumor-directed targeted therapies and immune therapies.

Based on the idea that each tumor has an independent genetic identity, his research aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation. One of his team ́s main objectives is to establish novel predictive markers of response to anti-cancer therapies and identify markers of primary resistance (de novo) and secondary treatment. At a preclinical level, the group he is leading is developing new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study the tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery, Clinical Cancer Research, Cancer Treatment Reviews and Nature Reviews in Clinical Oncology. He has (co) authored approximately 500 peer-reviewed papers.

He was the President of the European Society for Medical Oncology (ESMO) for the term 2018-2019, and is also member of the American- Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). He has also been a member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, TAT and WCGIC meetings.


Why WIN

At VHIO we are keen to both share our expertise as well as benefit from the experience of many others through international collaboration. We are particularly proud to be a member of the WIN consortium -  a combined tour de force behind original research projects led by private and academic institutions in cross-border and multidisciplinary unison.

Josep Tabernero logo

Josep Tabernero

Head, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH); Director, Vall d'Hebron Institute of Oncology, VHIO (Spain)


Vall d’Hebron Institute of Oncology (VHIO) logo

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and he is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO) and Professor of Medicine at UVic. He is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with tumor-directed targeted therapies and immune therapies.

Based on the idea that each tumor has an independent genetic identity, his research aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation. One of his team ́s main objectives is to establish novel predictive markers of response to anti-cancer therapies and identify markers of primary resistance (de novo) and secondary treatment. At a preclinical level, the group he is leading is developing new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study the tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery, Clinical Cancer Research, Cancer Treatment Reviews and Nature Reviews in Clinical Oncology. He has (co) authored approximately 500 peer-reviewed papers.

He was the President of the European Society for Medical Oncology (ESMO) for the term 2018-2019, and is also member of the American- Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). He has also been a member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, TAT and WCGIC meetings.


Why WIN

At VHIO we are keen to both share our expertise as well as benefit from the experience of many others through international collaboration. We are particularly proud to be a member of the WIN consortium -  a combined tour de force behind original research projects led by private and academic institutions in cross-border and multidisciplinary unison.